The SMART (Symbicort Maintenance and Reliever Therapy) approach allows patients to increase the dose of Symbicort (a combination of an inhaled corticosteroid and long-acting bronchodilator) during ...

AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...

The Scottish Medicines Consortium has given its seal of approval for the use of AstraZeneca’s latest asthma product, Symbicort SMART, on the country’s National Health Service. The Scottish Medicines ...

AstraZeneca has launched its latest weapon for the treatment of asthma - Symbicort SMART - in the UK, marking the first product offering both maintenance and reliever therapy in a single inhaler to ...

March 19, 2007 — Health Canada has approved budesonide plus formoterol fumarate dehydrate inhalation aerosol with a flexible regimen for the maintenance and rescue treatment of asthma in patients aged ...

Symbicort is an inhaler used for long-term control of asthma and COPD, but it is not a rescue inhaler. Before using Symbicort, tell your healthcare provider if you have health conditions like adrenal ...

(RTTNews) - The U.S. Food and Drug Administration approved Mylan Pharmaceuticals, Inc.'s generic of Symbicort (budesonide and formoterol fumarate dihydrate) inhalation aerosol. It is the first FDA- ...

AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort (formoterol and ...

Not enough drugmakers on the “smart inhaler” bandwagon for you? Well, go ahead and add AstraZeneca to the list. The British pharma giant is teaming up with Quintiles on a clinical trial to test ...

Symbicort, which is used to treat chronic obstructive pulmonary disease and asthma, can cause side effects. Mild side effects include nasal congestion and headaches. Serious side effects include ...

Ring up another win for Teva ($TEVA) in its fight to roll out a generic of AstraZeneca's Symbicort in Europe--and another loss for aging respiratory blockbusters ...